Replies to post #245120 on Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

Get Excited and get the media to pick up on IPIX. This is a feel good triumphant story - or it will be! Someone needs to pick up on this company and how it was attacked and continues to be attacked all while attempting to bring life saving/altering drugs to market. We need some good PR Art! This can take off and become a powerhouse! IMO.

[leavetheguntakethecannolis]

Thanks for the outstanding post Daubs. Great reminder for all here wavering and/or doubting the outcome. Buying many more shares when funds become available ASAP. It's gonna be quite the firework show sooner or later.

[AlanC]

Thanks for your great post. Your facts clearly illustrate why longs continue to accumulate as they are able. The pipeline is incredible.
Go IPIX!!!

[MXAMDUD]

the market has now caught on to the credibility issues of IPIX mgmt. The failure to execute. The false PR's that never happen. The toxic financing.

I will wager right now that nothing happens by year end except another PR stringing us along saying 'we're in negotiations blah blah blah".

that term sheet PR is just more BS like the 20 CDA's was

[BooDog]

Sticky worthy. And I stickied it. A lot has been going on this year. Not just with prurisol completing its phase, data pending. But also analyzing the brilacidin data and prepping it for breakthrough designation potential. Compiling data for the next stage, not to mention the term sheet that just may bring in the partnership to pay for it.

So much looking forward to seeing the fundamentals finally leap forward. They've been hard at work earning their paychecks imo. Takes time.

Then Sox will finally be able to update his post as well.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142367628

$IPIX

Message in reply to:

COMPARE FOR YOURSELF - 2012 to 2018 - IPIX $$$

AUGUST 31st 2012 - Closed at .63
September 31st 2012 - Closed at 1.00

In the 10-K released on 10/12/12 I found the below info. Here is link to 10-K (https://www.bamsec.com/filing/154823312000017?cik=1355250)

CASH ON HAND - $27,000
CTIX did not have any major Stock Purchase Agreements at the time! So no funds readily available.

OS as of SEPT 30th 2012 - - 93,124,151 (ABOUT 70 MILLION LESS than now)

They had ZERO CLINICAL trials - just pre-clinical work.

Some notes of accomplishments though:
Jan 2012 - Prurisol Patent Filed
March 2012 - BIDMC Agreement to test Keveterin
May 2012 - Jim Boeheim joined as advisor (lol) Jim is a good man but this was exciting at the time.
June 2012 - IND Meeting with FDA approved to seek section 505(b)(2)
June 2012 - IND approved by FDA to begin Phase 1 trial at Dana Farber and BIDMC for Keveterin
Sept 2012 - Selected Dr. Reddy's Lab to manufacturer P

COMPOUNDS OWNED BY CTIX in 2012: 8 TOTAL
Kevetrin
KM 133
KM 391
KM 277
KM 278
KM 362
KM-3174
KM-732

DESIGNATIONS: June 2012 for Prurisol - 505 (b)(2) Approach

_________________________________________________________________
_________________________________________________________________
FAST FORWARD ----- As of OCT 16 2018 -----------

OCTOBER 16th --- Close - .18
Total OS as of AUG 27th 2018 ----- 161,100,000 shares

Cash on hand: 2.4 Million

Financing in place: 22.3 MILLION available from ASPIRE
Financing in place: 75 Million Shelf Reg
Financing in place: 10 Million from MultiFamily Office

Compounds Owned in 2018:
ADDITIONAL COMPOUNDS OWNED AFTER POLYMEDIX's acquisition: 18 TOTAL
**THIS INCLUDES PATENTS** It also included "SUBSTANTIAL EQUIPMENT ASSETS"
"We are very excited about instantly having a strong antibiotic franchise to complement our already robust pipeline that now contains 18 compounds"

ACCOMPLISHMENTS:
CLINICAL TRIALS: (Daubs summary)
1) PHASE I: A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors
(Start: Oct 2012 - End: Feb 2016) SUCCESSFUL

2) PHASE 2B: Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections
(Start: Feb 2014 - END: Oct 2014) SUCCESSFUL
***Compared favorably to Daptomycin which is a blockbuster drug

3) PHASE I: Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers
(Start: March 2014 - End: Oct 2014) SUCCESFUL

4) PHASE II: Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis
(Start: Aug 2015 - End: May 2016) SUCCESSFUL

5) PHASE 2B: Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis
(Start: Oct 2016 - End: Dec 2017) TOP LINE WHEN WE PAY CRO

6) PHASE 2: Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer (Brilacidin)
(Start: May 2015 - End: Dec 2017) SUCCESSFUL
MGMT COMMENT:

Quote:
After a recent successful Phase 2 trial in Oral Mucositis (OM), the Company believes that it is the clear global leader in this area as it develops an easy-to-administer oral rinse medicine for the prevention of severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation—analysts estimate this market could reach $1 billion in coming years.


7) A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer
(Start: Feb 2017 - End: Feb 2018) SUCCESSFUL

8) A Phase 2 open label Proof-of-Concept trial evaluating Brilacidin as a new treatment for mild-to-moderate ulcerative proctitis/ulcerative proctosigmoiditis, two types of inflammatory bowel disease
(Start: June 2016 - End: June 2017) SUCCESSFUL

DESIGNATIONS FROM THE FDA:
Brilacidin -
1) QIDP Fast Track Designation ABSSSI - Dec 2014
2) Fast track Designation for OM - Nov 2015
***BREAKTHROUGH for B-OM has been applied for! Waiting on FDA - WITHIN NEXT 30 DAYS!
KEVETRIN -
3) Orphan Drug Designation for Ovarian Cancer - July 2015
4) Orphan Drug Designation for Retinoblastoma - Nov 2015
5) Rare Pediatric Disease Designation for Retinoblastoma - Nov 2015
(the case for Silver Spring-based United Therapeutics Corp., which sold a voucher for $350 million in 2015)
*Orphan Drug Designation for Pancreatic Cancer - Jan 2016


Approaching 20 CDA's with Big Pharm and other BIO's!

AUGUST 2018 --- NON-BINDING TERM SHEET SIGNED WITH GLOBAL BP for indications of B-OM and B-IBD!!!!

GOOD LUCK ALL!!!

[scottsmith]

I highlighted the parts that are fictitious.

"Financing in place: 22.3 MILLION available from ASPIRE
Financing in place: 75 Million Shelf Reg
Financing in place: 10 Million from MultiFamily Office "

[Hazelhurst]

Nice. I would add the contracts with Evonik and CoreRx for bulk production of commercial-grade Brilacidin and sachets. This is prepping towards B-OM Phase 3. Now just need some monetary assistance for a global biopharmaceutical company.

[DaubersUP]

$4.40 a share - Dec 31st 2014: Comparing to 2012 which should show just how undervalued we are with zero FAILURES in the clinic, here are some facts from when we were at the HIGH of IPIX:

Dec 31st 2014 - Share price - $4.40
Cash on hand - 9.4 million
Total OS - 117 Million (ish)
PROGRESS
1) Kevetrin - In Progress Phase 1 - Enrolling in the 10th cohort
2) Prurisol - Successful Phase 1 Completed - Comparing bio-availability b/w P and Ziagen
3) B-Absssi - Successful Phase 2b Completed - Topline data Oct 23rd - full data in 2015 to be announced
4) B-OM - IND filed in Sept 2014 and granted by FDA in Oct 2014

**2 Successful Human Trials to date**

https://www.bamsec.com/filing/147793215001033?cik=1355250
Posted in Feb2015 for Q ending Dec 31st 2014

August 27th 2018 - .40
Cash on hand - 2.4 million
Total OS - 163 Million
PROGRESS
1) Kevetrin - Phase 1 Successful (Solid Tumors)
2) Kevetrin - Phase 2 Successful (Ovarian)
3) Prurisol - Phase 2a Successful (Mild - Moderate Psoriasis)
4) Prurisol - Phase 2b Completed (Moderate - Severe Psoriasis) AWAITING DATE
5) B-OM - Phase 2 Successful (Oral Mucositis - PREVENTION) Leader in an untapped market
6) B-UP/UC - Phase 2 PoC Successful

**5 Additional late stage Human trials SUCCESSFUL - Awaiting data on a Phase 2b for Prurisol**


So to summarize - in 3.5 years IPIX was able to complete 5 SUCCESSFUL human trials and awaiting on data for a phase 2b.
The share count increased by about 45 Million shares.